
-
Oncternal Therapeutics NasdaqCM:ONCT Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.
Location: 12230 El Camino Real, San Diego, CA, 92130, United States | Website: https://www.oncternal.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
0.00
Cash
0.00
Avg Qtr Burn
N/A
Short % of Float
0.53%
Insider Ownership
9.23%
Institutional Own.
12.07%
Qtr Updated
09/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ONCT-808 (CAR-T) Details Hematologic malignancies, Cancer, B-cell lymphoma | Phase 1/2 Data readout | |
ONCT-534 Details Cancer, Castration-resistant prostate cancer | Failed Discontinued | |
Zilovertamab (Cirmtuzumab) (ROR1) + Ibrutinib Details Blood cancer, Cancer, Mantle cell lymphoma | Failed Discontinued | |
ONCT-216 (TK216) (EWS-FLI1 inhibitor) Details Relapsed/refractory Ewing sarcoma, Cancer | Failed Discontinued | |
Zilovertamab (Cirmtuzumab) (ROR1) + Paclitaxel Details Cancer, Metastatic breast cancer | Failed Discontinued | |
Zilovertamab (Cirmtuzumab) (ROR1) + Ibrutinib Details Blood cancer, Chronic lymphocytic leukemia, Cancer, Mantle cell lymphoma | Failed Discontinued |